Reata Pharmaceuticals Inc (NASDAQ:RETA) major shareholder James W. Traweek, Jr. acquired 17,000 shares of the business’s stock in a transaction that occurred on Saturday, December 29th. The shares were purchased at an average cost of $28.47 per share, for a total transaction of $483,990.00. Following the acquisition, the insider now owns 35 shares in the company, valued at $996.45. The acquisition was disclosed in a legal filing with the SEC, which is available through this hyperlink. Large shareholders that own more than 10% of a company’s shares are required to disclose their sales and purchases with the SEC.

Reata Pharmaceuticals Inc (NASDAQ RETA) opened at $28.32 on Tuesday. The company has a market capitalization of $739.52, a PE ratio of -18.51 and a beta of -3.11. Reata Pharmaceuticals Inc has a twelve month low of $19.48 and a twelve month high of $40.88. The company has a current ratio of 3.18, a quick ratio of 3.18 and a debt-to-equity ratio of -0.15.

Reata Pharmaceuticals (NASDAQ:RETA) last announced its earnings results on Monday, November 13th. The company reported ($0.50) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.39) by ($0.11). The business had revenue of $12.60 million during the quarter, compared to analysts’ expectations of $12.54 million. The business’s quarterly revenue was up .0% compared to the same quarter last year. equities analysts anticipate that Reata Pharmaceuticals Inc will post -1.91 earnings per share for the current fiscal year.

RETA has been the topic of several recent research reports. ValuEngine raised Reata Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Tuesday, September 26th. Zacks Investment Research raised Reata Pharmaceuticals from a “strong sell” rating to a “hold” rating in a report on Tuesday, October 24th. Cowen reissued a “buy” rating on shares of Reata Pharmaceuticals in a report on Tuesday, November 14th. Robert W. Baird reissued a “buy” rating and set a $47.00 price objective on shares of Reata Pharmaceuticals in a report on Tuesday, October 24th. Finally, BidaskClub downgraded Reata Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Tuesday, December 5th. Three research analysts have rated the stock with a sell rating and eight have assigned a buy rating to the company. The company presently has an average rating of “Hold” and a consensus target price of $54.71.

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Crestline Management LP acquired a new position in Reata Pharmaceuticals during the 3rd quarter worth about $1,880,000. First Allied Advisory Services Inc. acquired a new position in Reata Pharmaceuticals during the 3rd quarter worth about $203,000. Alyeska Investment Group L.P. acquired a new position in Reata Pharmaceuticals during the 3rd quarter worth about $2,832,000. California State Teachers Retirement System lifted its holdings in Reata Pharmaceuticals by 21.2% during the 3rd quarter. California State Teachers Retirement System now owns 18,325 shares of the company’s stock worth $570,000 after buying an additional 3,200 shares during the period. Finally, Schwab Charles Investment Management Inc. lifted its holdings in Reata Pharmaceuticals by 83.2% during the 3rd quarter. Schwab Charles Investment Management Inc. now owns 49,828 shares of the company’s stock worth $1,550,000 after buying an additional 22,628 shares during the period. 29.58% of the stock is currently owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION NOTICE: “Reata Pharmaceuticals Inc (RETA) Major Shareholder James W. Traweek, Jr. Purchases 17,000 Shares of Stock” was published by TheOlympiaReport and is the property of of TheOlympiaReport. If you are accessing this report on another site, it was illegally copied and republished in violation of US and international trademark and copyright laws. The original version of this report can be accessed at https://theolympiareport.com/2018/01/02/reata-pharmaceuticals-inc-reta-major-shareholder-james-w-traweek-jr-purchases-17000-shares-of-stock.html.

About Reata Pharmaceuticals

Reata Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on identifying, developing and commercializing product candidates that modulate the activity of regulatory proteins involved in the biology of mitochondrial function, oxidative stress, and inflammation to address the unmet medical needs of patients with a range of serious or life-threatening diseases.

Insider Buying and Selling by Quarter for Reata Pharmaceuticals (NASDAQ:RETA)

Receive News & Ratings for Reata Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Reata Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.